GVAX Plus Checkpoint Blockade in Neuroblastoma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
- Status
- TERMINATED
- Phase
- PHASE2
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
- Status
- RECRUITING
- Phase
- PHASE2
Cabozantinib and Nivolumab for Carcinoid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
- Status
- COMPLETED
- Phase
- PHASE2
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
- Status
- TERMINATED
- Phase
- PHASE1
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2